Page 128 - 2021_12-Haematologica-web

S. Bohler et al.
9. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202- 208.
10. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demon- strate fulminant lymphoid apoptosis, poly- cystic kidneys, and hypopigmented hair. Cell. 1993;75(2):229-240.
11. Yamamura K, Kamada S, Ito S, Nakagawa K, Ichihashi M, Tsujimoto Y. Accelerated dis- appearance of melanocytes in bcl-2-deficient mice. Cancer Res. 1996;56(15):3546-3550.
12. Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132-1144.
13. Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248- 1252.
14. Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946.
15. Birkinshaw RW, Gong JN, Luo CS, et al. Structures of BCL-2 in complex with veneto- clax reveal the molecular basis of resistance mutations. Nat Commun. 2019;10(1):2385.
16. Blombery P. Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. Leuk Lymphoma. 2020;61(2):257-262.
17. Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342-353.
18.Herling CD, Abedpour N, Weiss J, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lympho- cytic leukemia. Nat Commun. 2018;9(1): 727.
19. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905.
20. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in pro- grammed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A. 1993;90(8):3516-3520.
21. Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapop- totic protein possessing only the BH3 domain. J Biol Chem. 2000;275(33):25255- 25261.
22. KimJH,SimSH,HaHJ,KoJJ,LeeK,BaeJ. MCL-1ES, a novel variant of MCL-1, associ- ates with MCL-1L and induces mitochondr- ial cell death. FEBS Lett. 2009;583(17):2758- 2764.
23.Perciavalle RM, Stewart DP, Koss B, et al. Anti-apoptotic MCL-1 localizes to the mito- chondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol.
2012;14(6):575-583.
24. Rinkenberger JL, Horning S, Klocke B, Roth
K, Korsmeyer SJ. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 2000;14(1):23-27.
25. Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307(5712):1101-1104.
26. Delbridge AR, Opferman JT, Grabow S, Strasser A. Antagonism between MCL-1 and PUMA governs stem/progenitor cell sur- vival during hematopoietic recovery from stress. Blood. 2015;125(21):3273-3280.
27. Vo TT, Ryan J, Carrasco R, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012;151(2):344-355.
28. Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477-482.
29. Roelz R, Pilz IH, Mutschler M, Pahl HL. Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. Exp Hematol. 2010;38(9):792-797.
30. Labi V, Bertele D, Woess C, et al. Haematopoietic stem cell survival and trans- plantation efficacy is limited by the BH3- only proteins Bim and Bmf. EMBO Mol Med. 2013;5(1):122-136.
31. Afreen S, Bohler S, Muller A, et al. BCL-XL expression is essential for human erythro- poiesis and engraftment of hematopoietic stem cells. Cell Death Dis. 2020;11(1):8.
32. Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for ana- lyzing drug combination dose-response matrix data. Bioinformatics. 2020;36 (8):2645.
33. Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre- clinical models of acute myeloid leukemia. Leukemia. 2019;33(4):905-917.
34. Fiskus W, Cai T, DiNardo CD, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019;9(2):4.
35. Ramsey HE, Fischer MA, Lee T, et al. A novel MCL1 inhibitor combined with vene- toclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566-1581.
36. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoi- etic cells and neurons in Bcl-x-deficient mice. Science. 1995;267(5203):1506-1510.
37. Motoyama N, Kimura T, Takahashi T, Watanabe T, Nakano T. bcl-x prevents apop- totic cell death of both primitive and defini- tive erythrocytes at the end of maturation. J Exp Med. 1999;189(11):1691-1698. Delbridge AR, Aubrey BJ, Hyland C, et al. The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL. Cell Death Dis. 2017;8(7):e2914. Roberts AW, Davids MS, Pagel JM, et al.
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322.
40. Nakayama K, Nakayama K, Negishi I, Kuida K, Sawa H, Loh DY. Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lympho- cytopenia. Proc Natl Acad Sci U S A. 1994;91(9):3700-3704.
41. Matsuzaki Y, Nakayama K, Nakayama K, et al. Role of bcl-2 in the development of lym- phoid cells from the hematopoietic stem cell. Blood. 1997;89(3):853-862.
42. Campbell CJ, Lee JB, Levadoux-Martin M, et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood. 2010;116(9): 1433-1442.
43. Prukova D, Andera L, Nahacka Z, et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019;25(14):4455-4465.
44. Smith VM, Lomas O, Constantine D, et al. Dual dependence on BCL2 and MCL1 in T- cell prolymphocytic leukemia. Blood Adv. 2020;4(3):525-529.
45.Mukherjee N, Amato CM, Skees J, et al. Simultaneously inhibiting BCL2 and MCL1 is a therapeutic option for patients with advanced melanoma. Cancers (Basel). 2020;12(8):2182.
46. Abdul Rahman SF, Muniandy K, Soo YK, et al. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. Biochem Biophys Rep. 2020;22: 100756.
47. Slomp A, Moesbergen LM, Gong JN, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3(24):4202-4214.
48. Algarin EM, Diaz-Tejedor A, Mogollon P, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica. 2020;105(3):e116-e120.
49. Lee EF, Harris TJ, Tran S, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10(5):342.
50. Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S. Tyrosine kinase inhibitors Increase MCL1 degradation and in combina- tion with BCLXL/BCL2 inhibitors drive prostate cancer apoptosis. Clin Cancer Res. 2018;24(21):5458-5470.
51. Brennan MS, Chang C, Tai L, et al. Humanized Mcl-1 mice enable accurate pre- clinical evaluation of MCL-1 inhibitors des- tined for clinical use. Blood. 2018;132(15): 1573-1583.
52. Hird AW, Tron AE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol Ther. 2019;198:59-67.
53. www.ashclinicalnews.org; last accessed Nov 1, 2019.
54. Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341.
38.
39.
3148
haematologica | 2021; 106(12)